When compared with placebo, vunakizumab is a safe and efficacious treatment for moderate to severe plaque psoriasis among adults.

Discover a recent study from 12 hospitals across China that has shed new light on personalised care for plaque psoriasis.

And beyond the physical symptoms, plaque psoriasis also frequently has negative effects on mental health and alters the lifestyle of those living with it. Here are five ways that this skin condition ...

Research shows lifestyle changes like diet, exercise, and smoking cessation can assist with improving psoriasis outcomes and ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

NCT04785326), which compared the biosimilar to Stelara in patients with moderate to severe chronic plaque psoriasis. Findings showed the products were similar in pharmacokinetics, safety ...

The efficacy and safety of risankizumab remains similar across racial and ethnic groups of patients with moderate to severe plaque psoriasis.

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are ... extending its use into other chronic inflammatory diseases like ...

"The results from this study are aligned with our commitment to elevate the standard of care for the millions of adults impacted by moderate to severe plaque psoriasis, many of whom are currently ...

It is approved for use in rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and adults with chronic moderate-to-severe plaque psoriasis. In clinical ...